

NextCell provides update on timing of ProTrans-Young results

NextCell Pharma AB (publ) ("NextCell" or the "Company") announces that topline results from the ProTrans-Young clinical trial have not yet been reported to the company. The extended timeline is due to the final administrative processing and sign-off of study data taking longer than planned and is not related to the outcome of the study. The data are now being handled by statisticians at Uppsala Clinical Research Center (UCR).

ProTrans-Young is an investigator-initiated study sponsored by Uppsala University, with Professor Per-Ola Carlsson as Principal Investigator. The study includes a total of 66 children and young adults with recently diagnosed type 1 diabetes.

Before statistical analysis, study data in the electronic case report form (eCRF) must be reviewed and signed off by the relevant members of the study teams. For administrative reasons, this process has taken considerably longer than originally anticipated. The final sign-off has now been completed and the data are being handled by statisticians at UCR.

The result from the statistical analysis has not yet been reported to the Principal Investigator and NextCell therefore does not have access to any study results. Once the results are reported to Professor Per-Ola Carlsson, they will be shared with NextCell without delay, after which the company will publish the topline results through a press release.

For more information, please contact:

Mathias Svahn, CEO

Eric Gustafsson, CFO

Tel: +46 (0)8-735 55 95

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.

RedEye Noridc Growth AB is the company's Certified Adviser.

About NextCell Pharma AB

NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company's lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.